HER2-Positive Metastatic Breast Cancer Treatment Study
Part of Cancer, Skin clinical trials.
This study looks at how patients with advanced breast cancer (HER2-positive type) respond to anti-HER2 drugs over time. Researchers in Kazakhstan are reviewing medical records to understand which treatments work best and help improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with HER2-positive metastatic (advanced) breast cancer
- Your diagnosis was made between January 2022 and December 2023
- You are currently receiving or have started anti-HER2 therapy (cancer drugs targeting HER2)
- You are at least 18 years old
- Your medical records show at least 24 months of follow-up information since your diagnosis
- You have not received the drug trastuzumab deruxtecan (Enhertu)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well newer treatments work for advanced or metastatic breast cancer and why some people respond better than others. It is for anyone with HR-positive, HER2-positive/low, or triple-negative breast cancer who has started at least one treatment cycle.
This study looks at different types of HER2-positive breast cancer to learn more about the disease. It is for people with early-stage or locally advanced breast cancer who have not yet received treatment, and aims to help doctors find better ways to personalize care.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
This study tracks how patients with HER2-positive early-stage breast cancer receive treatment and stick to their treatment plan after their care moves to local hospitals. The trial helps doctors understand whether patients follow through with their recommended therapy when treated closer to home.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.